Had a wonderful day discussing how to move neph clinical trials forward. Congrats and well done to the Glomcon team. Great start to inaugural in-person conference.
Brad H Rovin retweeted
My #850challenge post to #sockittokidneydisease today - what better?! meeting than a kidney scientific π§« collaborative discussion with β¦@PepaSolerRβ©βs awesome team β¦πͺπΈβ© - & an opportunity to compare our β¦@worldkidneydayβ© & advocacy bracelets!! β€οΈ π«
Brad H Rovin retweeted
Replying to @BradRovin
#Ferrari @PepaSolerR Pepa and I toured the Ferrari Museum outside #Bologna after the Common Grounds Nephrology Meeting
Brad H Rovin retweeted
Enjoying a talk by @BradRovin #IgA at #commongrounds23 #Bologna New treatments and #therapies coming. Future with less progression. Proposed #flowcart @ComaiGiorgia
#IgANTreatment Great news for patients and docs. The data from the NefIgArd trial that led to accelerated approval of Nefecon for the treatment of IgAN just out in Kidney International on line. First of many new therapies for IgAN!π€HTTPS://www.kidney-internatiβ¦
Brad H Rovin retweeted
A challenge to the kidney community by a man-made crisis
doi.org/10.1016/j.kint.2022.β¦
@pi_ronco @BradRovin @germjacq #UkraineRussiaWar #CKD #hemodialysis #kidneytransplant
Brad H Rovin retweeted
Congratulations @goKDIGO for winning the #NephJCKidneys Award for Article of the Year 2021
#VisualAbstract by @michaelturk6 #NephJC
π kdigo.org/wp-content/uploadsβ¦
π kdigo.org/wp-content/uploadsβ¦
#IgAN The FDA approved budesonide (Tarpeyo) for IgAN. Accelerated approval was based on proteinuria with GFR data to follow. A success critical for drug development for GN in general, and a milestone for our IgA patients. Congrats and thanks to all who participated in this trial!
Brad H Rovin retweeted
Great article on "The lupus nephritis management resistance" Co-authored by our own @BradRovin
Click the link below and check it out! @SalemAlmaani @JasonProsek #WhatsUpWednesday #NephRocks @OSUWexMed
authors.elsevier.com/a/1e0TMβ¦
Brad H Rovin retweeted
π’ The πππππππ‘π ππ¦ ππ£π£π₯π’πππππ‘π.
Apply for the ISN-@Kidney_Int Editorial Fellowship by June 1, a non-funded position designed for early career professionals/academics working in the field of nephrology, dialysis, and transplantation.
theisn.org/blog/2021/05/11/iβ¦
#ClinicalTrialsDay Today is clinical trials day 2021. Thanks to all the patients and families who have participated in Nephrology trials, and all the trial professionals who manage studies. Your efforts are really moving kidney therapeutics forward at a rapid pace!
#voclolinkLN. Hi everyone. Woke up to find the link I sent to the Lancet Aurora article is not working. Mia culpa. This social media stuff is not molecular biology but at least I can do the latter. I have enlisted one of my tech savvy faculty, Salem Almaani to help retweet link.
2
26
#voclosporindata. Hello friends and colleagues. The publication of the AURORA trial is out online. Please see at this link: authors.elsevier.com/c/1d1Y3β¦ Brad
Brad H Rovin retweeted
Guess who came by for a surprise visit today and was able to sneak a pic. The GOAT himself, Dr. Lee Hebert...
Greatest Of All Time! We Miss You π
#WhatsUpWednesday #Vaccinated #NephRocks
Brad H Rovin retweeted
Help us Congratulate our own Dr. Josh Leisring in passing his Hypertension Boards & now a Certified Hypertension Specialist! Such an amazing accomplishment & helps support his new Resistant Hypertension Clinic!
LET'S GIVE HIM A SHOUT-OUT!
#FacultyFriday @OSUWexMed #NephRocks
#ApprovedforLupusNephritis More great news for our lupus nephritis patients. The FDA has just approved Voclosporin for the treatment of LN...and this regimen uses less glucocorticoid! This has been an exciting time for the lupus community.
#vaccinetoday I received my first dose of vaccine today. Only side effect is a profound feeling of inspiration at what the international community accomplished working together. Go science!! Imagine what else we can solve together, and not just in medicine.
#LupusNephritisTreatment Yesterday was a milestone for the lupus community as the FDA approved belimumab for the treatment of LN. Good news just in time for the new year! A big thanks to all the patients, families and investigators who made this progress possible!






















